HighVista Strategies LLC Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

HighVista Strategies LLC lifted its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 32.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,107 shares of the company's stock after purchasing an additional 12,899 shares during the period. Keros Therapeutics accounts for approximately 1.0% of HighVista Strategies LLC's portfolio, making the stock its 29th largest position. HighVista Strategies LLC owned 0.13% of Keros Therapeutics worth $3,026,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Alkeon Capital Management LLC boosted its holdings in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock valued at $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock valued at $12,990,000 after purchasing an additional 199,245 shares in the last quarter. FMR LLC increased its position in shares of Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after buying an additional 179,374 shares during the period. Emerald Advisers LLC bought a new position in Keros Therapeutics in the third quarter worth about $9,032,000. Finally, Holocene Advisors LP lifted its holdings in Keros Therapeutics by 22.5% in the third quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock worth $48,959,000 after buying an additional 154,784 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Analyst Ratings Changes

KROS has been the subject of several research reports. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating for the company. Guggenheim began coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a "buy" rating and a $96.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Scotiabank initiated coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $88.89.

Keros Therapeutics Stock Performance

KROS traded up $5.55 during trading on Tuesday, hitting $62.28. 594,945 shares of the company's stock traded hands, compared to its average volume of 408,812. Keros Therapeutics, Inc. has a 12-month low of $27.31 and a 12-month high of $73.00. The company's 50 day simple moving average is $59.49 and its two-hundred day simple moving average is $52.28.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million during the quarter. During the same period in the previous year, the business posted ($1.33) earnings per share. Keros Therapeutics's quarterly revenue was up 4750.0% on a year-over-year basis. Research analysts anticipate that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.